Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.

[1]  D. Clark,et al.  Detection of cervical high‐grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx™ C) , 2006, Cancer.

[2]  Steven J. M. Jones,et al.  Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Akslen,et al.  Gene expression in poorly differentiated papillary thyroid carcinomas. , 2006, Thyroid : official journal of the American Thyroid Association.

[4]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[5]  Mark F van Delft,et al.  How the Bcl-2 family of proteins interact to regulate apoptosis , 2006, Cell Research.

[6]  L. Akslen,et al.  Importance of P-Cadherin, β-Catenin, and Wnt5a/Frizzled for Progression of Melanocytic Tumors and Prognosis in Cutaneous Melanoma , 2005, Clinical Cancer Research.

[7]  D. Malinowski.  Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. , 2005, BioTechniques.

[8]  Akhilesh Pandey,et al.  Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags , 2004, Cancer biology & therapy.

[9]  Y. Nikiforov,et al.  Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.

[10]  A. Maitra,et al.  Met Proto-Oncogene and Insulin-Like Growth Factor Binding Protein 3 Overexpression Correlates with Metastatic Ability in Well-Differentiated Pancreatic Endocrine Neoplasms , 2004, Clinical Cancer Research.

[11]  D. Clark,et al.  Mutational Analysis of BRAF in Fine Needle Aspiration Biopsies of the Thyroid: A Potential Application for the Preoperative Assessment of Thyroid Nodules , 2004, Clinical Cancer Research.

[12]  L. Akslen,et al.  Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Gerhard Christofori,et al.  Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.

[14]  Christine A Iacobuzio-Donahue,et al.  Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. , 2003, Cancer research.

[15]  E. Fonseca,et al.  E‐cadherin loss rather than β‐catenin alterations is a common feature of poorly differentiated thyroid carcinomas , 2003, Histopathology.

[16]  David Yang,et al.  Identification of cervical cancer markers by cDNA and tissue microarrays. , 2003, Cancer research.

[17]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[18]  M. Santoro,et al.  Molecular Mechanisms of RET Activation in Human Cancer , 2002, Annals of the New York Academy of Sciences.

[19]  G. Christofori,et al.  Cadherins and the tumour progression: is it all in a switch? , 2002, Cancer letters.

[20]  C Eng,et al.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Moreno-Bueno,et al.  The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma , 2001, Modern Pathology.

[22]  B. Dörken,et al.  Bax expression in benign and malignant thyroid tumours: Dysregulation of wild‐type P53 is associated with a high Bax and P21 expression in thyroid carcinoma , 2001, International journal of cancer.

[23]  A. Vecchione,et al.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.

[24]  C. Cheung,et al.  Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[25]  A. P. Soler,et al.  P‐cadherin expression in breast carcinoma indicates poor survival , 1999, Cancer.

[26]  C. Cordon-Cardo,et al.  Bcl-2 and Bax expression in thyroid tumours An immunohistochemical and Western blot analysis , 1997, Virchows Archiv.

[27]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[28]  S. Asa,et al.  High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[29]  H. Gharib,et al.  Fine-Needle Aspiration Biopsy of the Thyroid: An Appraisal , 1993, Annals of Internal Medicine.

[30]  S. Rubin,et al.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.

[31]  S. Hirohashi,et al.  Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. , 1989, Cancer research.

[32]  A R Zinsmeister,et al.  Fine-Needle Aspiration Biopsy of the Thyroid: The Problem of Suspicious Cytologic Findings , 1984 .

[33]  O. Sakallioglu,et al.  Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. , 2007, American journal of otolaryngology.

[34]  A. D. De Marzo,et al.  Practical methods for tissue microarray construction. , 2005, Methods in molecular medicine.

[35]  B. Szende,et al.  bcl2, p53 and bax in thyroid tumors and their relation to apoptosis. , 2001, Neoplasma.